Use and effectiveness of adjuvant chemotherapy for stage III colon cancer: A population-based study

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 14, Issue 1, 2016, Pages 47-56

  Booth, Christopher M ^a,b   Nanji, Sulaiman ^b   Wei, Xuejiao ^a   Peng, Yingwei ^b   Biagi, James J ^b   Hanna, Timothy P ^a,b   Krzyzanowska, Monika K ^c   Mackillop, William J ^a,b  

^a QUEEN S UNIVERSITY   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; FLUOROURACIL; OXALIPLATIN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; COLON CANCER; DRUG EFFICACY; DRUG USE; FEMALE; HUMAN; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; SOCIAL STATUS; VERY ELDERLY; CANCER GRADING; COLONIC NEOPLASMS; COMORBIDITY; DISEASE MANAGEMENT; HEALTH SURVEY; MORTALITY; ONTARIO; PATHOLOGY; REGISTER; SOCIOECONOMICS; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; COMORBIDITY; DISEASE MANAGEMENT; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; ONTARIO; POPULATION SURVEILLANCE; REGISTRIES; RETROSPECTIVE STUDIES; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85007051435     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2016.0006     Document Type: Article

References (35)

1. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990;264:1444-1450.
2. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995;345:939-944.
3. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatmentfor colon cancer. N Engl J Med 2004;350:2343-2351.
4. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:2696-2704.
5. Benson AB, Venook AP, Bekaii-Saab T, et al. NCCN Clinical Practice Guidelines in Oncology for Colon Cancer. Version 1.2015. Available at: NCCN.org. Accessed September 14, 2015. To view the most recent version of these guidelines, visit NCCN.org.
6. Schmoll HJ, Van CE, Stein A, et al. ESMO consensus guidelines for management of patients with colon and rectal cancer. Ann Oncol 2012;23:2479-2516.
7. Jonker DJ, Spithoff K, Maroun J. Adjuvant systemic chemotherapy for stage II and III colon cancer after complete resection. Clin Oncol (R Coll Radiol) 2011;23:314-322.
8. Peppercorn JM, Weeks JC, Cook EF, et al. Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet 2004;363:263-270.
9. Templeton AJ, Vera-Badillo FE, Wang L, et al. Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Ann Oncol 2013;24:2972-2977.
10. Booth CM, Siemens DR, Li G, et al. Perioperative chemotherapy for muscle-invasive bladder cancer: a population-based outcomes study. Cancer 2014;120:1630-1638.
11. Meyer RM. Generalizing the results of cancer clinical trials. J Clin Oncol 2010;28:187-189.
12. Booth CM, Mackillop WJ. Translating new medical therapies into societal benefit: the role of population-based outcome studies. JAMA 2008;300:2177-2179.
13. Booth CM, Tannock IF. Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. Br J Cancer 2014;110:551-555.
14. Sundararajan V, Mitra N, Jacobson JS, et al. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med 2002;136:349-357.
15. Zuckerman IH, Rapp T, Onukwugha E, et al. Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with stage III colon cancer. J Am Geriatr Soc 2009;57:1403-1410.
16. Boland GM, Chang GJ, Haynes AB, et al. Association between adherence to National Comprehensive Cancer Network treatment guidelines and improved survival in patients with colon cancer. Cancer 2013;119:1593-1601.
17. Chagpar R, Xing Y, Chiang YJ, et al. Adherence to stage-specific treatment guidelines for patients with colon cancer. J Clin Oncol 2012;30:972-979.
18. Winget M, Hossain S, Yasui Y, et al. Characteristics of patients with stage III colon adenocarcinoma who fail to receive guideline-recommended treatment. Cancer 2010;116:4849-4856.
19. Sanoff HK, Carpenter WR, Sturmer T, et al. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J Clin Oncol 2012;30:2624-2634.
20. Lindskog EB, Gunnarsdottir KA, Derwinger K, et al. A population-based cohort study on adherence to practice guidelines for adjuvant chemotherapy in colorectal cancer. BMC Cancer 2014;14:948.
21. Murphy CC, Harlan LC, Lund JL, et al. Patterns of colorectal cancer care in the United States: 1990-2010. J Natl Cancer Inst 2015;107:djv198.
22. Iwashyna TJ, Lamont EB. Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer. J Clin Oncol 2002;20:3992-3998.
23. Clarke EA, Marrett LD, Krieger N. Cancer registration in Ontario: a computer approach. In: Jenson OM, Parkin DM, MacLennan R, eds. Cancer Registration Principles and Methods. Lyon, France: IARC; 1991:246-257.
24. Li X, King C, deGara C, et al. Validation of colorectal cancer surgery data from administrative data sources. BMC Med Res Methodol 2012;12:97.
25. Mackillop WJ, Zhang-Salomons J, Groome PA, et al. Socioeconomic status and cancer survival in Ontario. J Clin Oncol 1997;15:1680-1689.
26. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-619.
27. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997;127:757-763.
28. Sanoff HK, Carpenter WR, Martin CF, et al. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. J Natl Cancer Inst 2012;104:211-227.
29. Schrag D, Cramer LD, Bach PB, et al. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 2001;93:850-857.
30. Cree M, Tonita J, Turner D, et al. Comparison of treatment received versus long-standing guidelines for stage III colon and stage II/III rectal cancer patients diagnosed in Alberta, Saskatchewan, and Manitoba in 2004. Clin Colorectal Cancer 2009;8:141-145.
31. Rayson D, Urquhart R, Cox M, et al. Adherence to clinical practice guidelines for adjuvant chemotherapy for colorectal cancer in a Canadian province: a population-based analysis. J Oncol Pract 2012;8:253-259.
32. Twelves C, Scheithauer W, McKendrick J, et al. Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol 2012:23:1190-1197.
33. Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27:3109-3116.
34. Williams J, Young W. A summary of studies on the quality of health care administrative databases in Canada. In: Goel V, Williams JI, Anderson GM, et al, eds. Patterns of Health Care in Ontario: The ICES Practice Atlas, 2nd ed. Ottawa, Canada: Canadian Medical Association; 1996:339-345.
35. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011;46:399-424.